Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Sep. 30, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Phil Febbo [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Phil Febbo, Chief Scientific Officer and Chief Medical Officer, adopted a new trading plan on August 12, 2026 (with the first trade under the new plan scheduled for approximately November 30, 2026). The trading plan will be effective until November 26, 2027 to sell an aggregate of (i) 8,000 shares of our common stock, plus (ii) between 50% and 100% of the net shares resulting from the vesting of 87,844 restricted stock units during the plan period (net shares are net of tax withholding). |
| Name | Phil Febbo |
| Title | Chief Scientific Officer and Chief Medical Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | August 12, 2026 |
| Expiration Date | November 26, 2027 |
| Arrangement Duration | 471 days |
| Phil Febbo Trading Arrangement, Common Stock [Member] | Phil Febbo [Member] | |
| Trading Arrangements, by Individual | |
| Aggregate Available | 8,000 |
| Phil Febbo Trading Arrangement, Vested Restricted Stock Units (RSUs) [Member] | Phil Febbo [Member] | |
| Trading Arrangements, by Individual | |
| Aggregate Available | 87,844 |